文献速递生殖医学母胎医学

常规血清促甲状腺激素检测——优化孕前健康还是产生毒性知识?

Routine serum thyroid-stimulating hormone testing-optimizing pre-conception health or generating toxic knowledge?
PubMed 文献 · Hum Reprod · 2017-01-01

本文讨论无症状女性孕前常规筛查亚临床甲状腺功能减退(SCH)并优化血清促甲状腺激素(TSH)至<2.5 mIU/l的策略。作者指出现有随机试验不太可能回答该问题,该策略可能改善子代健康,也可能因焦虑、增加用药和终身监测而产生毒性知识,仅大型设计良好的研究才能揭示答案。

要点

  • 专业内分泌学会呼吁孕前优化血清TSH水平,推荐<2.5 mIU/l。
  • 现有随机试验不太可能回答无症状女性孕前常规筛查SCH是否有益。
  • 筛查策略可能改善子代健康,也可能产生焦虑、增加用药和终身监测的毒性知识。

核心结论

  • 常规孕前筛查SCH并优化甲状腺状态可能对子代产生显著健康获益,也可能被证明是产生毒性知识、导致焦虑、增加药物使用和潜在伤害的昂贵方式,仅大型设计良好的研究才能揭示答案。

研究设计与样本

  • 本文为论述性文章,讨论无症状女性孕前常规血清TSH检测及优化甲状腺状态的策略,未报告系统检索范围或样本量。

主要发现

  • 现有系统综述提示母亲SCH与不良产科和新生儿结局存在关联,但妊娠期开始给予甲状腺素未能显示可察觉的健康获益。
  • 将孕前血清TSH优化至<2.5 mIU/l的策略产生相当大的不确定性,部分因该推荐水平低于既往用于定义该病的水平,部分因临床医生在此背景下最佳筛查方案的不确定性。
  • 重新校准预期正常围受孕血清TSH范围(<2.5 mIU/l)将显著影响临床服务,因诊断为SCH并需检查、治疗和监测的女性数量不可避免增加。
  • 血清TSH符合筛查试验标准且口服甲状腺素为廉价药物,因此没有理由认为不能对所有计划妊娠的女性进行筛查。
  • 该方法将遗漏意外妊娠的女性,并产生焦虑、进一步检查和更多甲状腺素处方,同时受影响女性需终身监测。

关键数值与推荐

  • 专业内分泌学会呼吁孕前优化血清TSH水平。
  • 确保孕前血清TSH水平低于2.5 mIU/l的策略被讨论,但该推荐水平低于既往用于定义SCH的水平。

局限性

  • 现有和正在进行的随机试验不太可能回答无症状女性孕前常规筛查SCH是否有益的问题。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Monitoring subclinical hypothyroidism (SCH) in women is believed to be important in terms of preventing overt hypothyroidism and optimizing the health and cognitive development of their children. Current systematic reviews have suggested an association between maternal SCH and adverse obstetric and neonatal outcomes. However, initiating the administration of thyroxine during pregnancy has failed to demonstrate appreciable health benefits. Hence there are calls by professional endocrine societies for optimizing serum thyroid-stimulating hormone (TSH) levels pre-conception. The strategy of ensuring that serum TSH levels are below 2.5 mIU/l during the pre-conception period has generated considerable uncertainty partly because the recommended level of <2.5 mIU/l is lower than those previously used to define the condition and partly due to uncertainty about the best screening programme clinicians can use in this context. Recalibrating the expected normal peri-conceptional range of serum TSH (<2.5 mIU/l), will have a significant impact on clinical services due to an inevitable increase in numbers of women diagnosed with SCH who will need to be investigated, treated and monitored. Serum TSH fulfils the criteria for a screening test and oral thyroxine is an inexpensive drug. Therefore, there is no reason to believe that screening cannot be undertaken in all women planning to conceive. Yet this approach will miss women whose pregnancies are unplanned and generate anxiety, further tests and many more prescriptions for thyroxine, coupled with the need for lifelong monitoring in affected women. A number of existing and ongoing randomized trials have evaluated the use of thyroxine in women with infertility or miscarriage with detectable thyroid auto-antibodies. These are unlikely to answer the question whether routine pre-conception testing for SCH in asymptomatic women is beneficial. Routine screening of women at risk of pregnancy and optimization of their thyroid status could result in significant health benefits for their offspring. Alternatively this approach could prove to be an expensive way of generating toxic knowledge resulting in anxiety, increased drug use and potential harm. Only large, appropriately designed studies can reveal the answer.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Maheshwari A, Bhide P, Pundir J, et al. Routine serum thyroid-stimulating hormone testing-optimizing pre-conception health or generating toxic knowledge? Hum Reprod. 2017. PMID: 28854714. doi:10.1093/humrep/dex240

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。